GSK plc (GSK)
GSK plc (GSK) carries a ŷRobot AI score of 58 out of 100. The model's fair value estimate is $50.01, 0.9% below the last close of $50.46. The chart signal reads Bearish.
| Metric | GSK |
|---|---|
| AI score | 58 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $50.01 |
| Upside to fair value | -0.9% |
| Previous close | $50.46 |
| P/E | 16.96 |
| Price / sales | 2.17 |
| Market cap | $101.48B |
| EPS | 2.87 |
| Revenue growth | 5.9% |
| 1-year price change | 2.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about GSK
Is GSK overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates GSK plc (GSK) at $50.01 against a last close of $50.46, implying 0.9% downside to the model's estimate.
Is GSK's chart signal bullish or bearish?
The chart-signal model classifies GSK as Neutral as of Nov 13, 2026, with a signal score of -0.08 on a -1 to 1 scale.
What is GSK's ŷRobot AI score?
GSK scores 58 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is GSK stock expensive on P/E and P/S?
GSK trades at 17.0 times earnings and 2.2 times sales as of Nov 13, 2026.
What does GSK's seasonal forecast show?
ŷRobot's seasonal forecast curve for GSK reads +1.8% at 30 days, +4.9% at 90 days, and +2.5% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is GSK growing?
GSK plc's revenue growth is +5.9% and free-cash-flow growth is +20.1% on the latest reported figures.
GSK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.